An evaluation of liraglutide including its efficacy and safety for the treatment of obesity

  title={An evaluation of liraglutide including its efficacy and safety for the treatment of obesity},
  author={Chen-Hsiu Lin and Li Shao and Yumei Zhang and Yu-Ju Tu and Yuzhen Zhang and Brian Tomlinson and Paul Chan and Zhongmin Liu},
  journal={Expert Opinion on Pharmacotherapy},
  pages={275 - 285}
ABSTRACT Introduction: The prevalence of obesity is increasing worldwide and associated conditions, particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle intervention should be the first line of management for obesity but additional pharmacotherapy is often required and bariatric surgery is appropriate in more severe cases. Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and… Expand
Future directions in obesity pharmacotherapy.
  • N. Finer
  • Medicine
  • European journal of internal medicine
  • 2021
Current regulatory requirements are out of step with the efficacy of new compounds and concepts relating to obesity and its complications, raising the possibility of drug combinations to maximise efficacy as for other chronic disease such as hypertension and diabetes. Expand
SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise. Expand
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential
An overview of preclinical studies that demonstrate GLP-1 RAs improve cognition and comment on their potential therapeutic benefit in individuals with schizophrenia are provided. Expand
Liraglutide for management of adolescent obesity
A new randomized, controlled trial provides evidence of efficacy of a pharmacological therapy, liraglutide, for weight control in adolescent obesity. Expand
Cajanolactone A, a Stilbenoid From Cajanus canjan (L.) Millsp, Prevents High-Fat Diet-Induced Obesity via Suppressing Energy Intake
It was found that treatment with CLA reduced the energy intake and effectively protected the mice from HFD-induced body weight gain, fat accumulation within the adipose tissues and liver, and impairment in energy metabolism, suggesting that CLA is a potential drug candidate for preventing diet-induced obesity, at least in females. Expand
Identification of Reactive Hypoglycemia with Different Basic BMI and Its Causes by Prolonged Oral Glucose Tolerance Test
Obese people has higher rate of reactive hypoglycemia than other groups in POGTT, in which insulin resistance may play an important role, but patients who are evaluated for reactive hypglycemia need to be observed for at least 3 or 4 hours. Expand
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights
Accumulating evidence suggests that IBTs may favorably alter the clinical course of SARS-CoV-2 infection due to their inherent mechanisms of action, and further research into prognostic variables associated with various antidiabetic treatment regimens, and in particular the IBT, is warranted. Expand


Liraglutide in the treatment of obesity
Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, which has a protracted pharmacokinetic profile compared to native GLP- 1 while maintaining its biological activity and has clinically relevant significance on reducing obesity-related morbidity and mortality. Expand
Liraglutide: A Review of Its Use in the Management of Obesity
Subcutaneous liraglutide was significantly more effective than placebo in terms of reductions in fasting bodyweight and waist circumference, and improvements in some biomarkers of cardiovascular risk, in nondiabetic adults with moderate to severe OSA. Expand
Liraglutide for type 2 diabetes mellitus
Liraglutide, a once-daily GLP-1 analog, has a definite role in selected patients with T2DM and the long-term cardiovascular safety is currently being ascertained in ongoing trials. Expand
Liraglutide for Type 2 diabetes and obesity: a 2015 update
The major clinical trials evaluating the effects of liraglutide in obesity and T2DM are covered and novel insights into the pharmacological mechanisms are provided. Expand
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
The effects of liraglutide on insulin and glucagon secretion are glucose dependent, and hence the risk of hypoglycaemia is low, and the pharmacokinetic and pharmacodynamic properties make it an important treatment option for many patients with type 2 diabetes. Expand
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
This randomized, double-blind, placebo-controlled, parallel-group trial with 12-week observational off-drug follow-up period to investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes. Expand
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control in patients with type 2 diabetes and prediabetes. Expand
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity-related risk factors, and reduces prediabetes. Expand
Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long‐Acting, Potent Glucagon‐Like Peptide‐1 Analog
Liraglutide is a once‐daily GLP‐1 analog that has been recently approved by the European Union regulatory agency and is in late‐stage review by the United States Food and Drug Administration for the treatment of type 2 diabetes. Expand
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses. Expand